Related Experiment Video

Updated: May 11, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

Neuromodulation device therapy for treatment of hypertensive heart disease

Thomas M Todoran1, Michael R Zile

  • 1Division of Cardiology, Medical University of South Carolina, Charleston, SC, USA. todoran@musc.edu

Circulation Journal : Official Journal of the Japanese Circulation Society
|May 10, 2013
PubMed

Insights

Hypertensive heart disease (HHD) is a major health issue. Neuromodulation device therapy shows promise for treating HHD by addressing autonomic nervous system imbalances.

Area of Science:

  • Cardiology
  • Neurology
  • Medical Devices

Background:

  • Hypertensive heart disease (HHD) is a primary cause of death and illness in the U.S.
  • Current medical therapies for HHD present treatment challenges.
  • Autonomic nervous system (ANS) imbalance, specifically sympathetic overactivity and parasympathetic underactivity, is key in hypertension and HHD development.

Purpose of the Study:

  • To explore the potential of neuromodulation device therapy for treating HHD.
  • To investigate the role of ANS imbalance in HHD pathogenesis.

Main Methods:

  • Review of emerging data on neuromodulation device therapy.
  • Analysis of the physiological mechanisms linking ANS imbalance to HHD.

Main Results:

  • Emerging data indicates neuromodulation device therapy is a promising approach for HHD.
  • ANS dysfunction is a critical factor in the progression of hypertension to HHD.

Conclusions:

  • Neuromodulation device therapy presents a novel and promising avenue for HHD treatment.
  • Targeting ANS imbalance may offer a new strategy for managing hypertensive heart disease.

More Related Videos

Non-Invasive Electrical Brain Stimulation Montages for Modulation of Human Motor Function07:47

Non-Invasive Electrical Brain Stimulation Montages for Modulation of Human Motor Function

Published on: February 4, 2016

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.